Rep. Bruce Westerman Acquires Shares of Abbott Laboratories (NYSE:ABT)

Representative Bruce Westerman (R-Arkansas) recently bought shares of Abbott Laboratories NYSE: ABT. In a filing disclosed on April 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in Abbott Laboratories stock on March 3rd. The trade occurred in the Representative's "FISHER IRA" account.

Representative Bruce Westerman also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of LVMH Moët Hennessy - Louis Vuitton, Société Européenne OTCMKTS: LVMUY on 4/2/2025.
• Purchased $1,001 - $15,000 in shares of Sony Group NYSE: SONY on 3/24/2025.
• Purchased $1,001 - $15,000 in shares of Mitsubishi UFJ Financial Group NYSE: MUFG on 3/21/2025.
• Purchased $1,001 - $15,000 in shares of BP NYSE: BP on 3/21/2025.
• Sold $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Medtronic NYSE: MDT on 3/20/2025.
• Purchased $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 3/20/2025.

Abbott Laboratories Trading Down 1.7 %

ABT stock traded down $2.28 during mid-day trading on Wednesday, reaching $129.45. 5,262,468 shares of the stock traded hands, compared to its average volume of 6,027,959. Abbott Laboratories has a 52-week low of $99.71 and a 52-week high of $141.23. The stock's fifty day moving average is $130.61 and its 200-day moving average is $122.15. The company has a market cap of $224.51 billion, a P/E ratio of 16.92, a P/E/G ratio of 2.52 and a beta of 0.80. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.02. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.38 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. As a group, sell-side analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a $0.59 dividend. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.82%. Abbott Laboratories's payout ratio is currently 30.61%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ABT. Redwood Park Advisors LLC bought a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $25,000. Noble Wealth Management PBC acquired a new position in Abbott Laboratories during the 4th quarter valued at $26,000. NewSquare Capital LLC grew its position in Abbott Laboratories by 78.4% in the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock worth $27,000 after purchasing an additional 105 shares during the last quarter. WealthTrak Capital Management LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter valued at about $28,000. Finally, Rialto Wealth Management LLC bought a new position in Abbott Laboratories during the fourth quarter valued at about $29,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on ABT shares. Royal Bank of Canada upped their target price on Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a report on Thursday, April 17th. Barclays increased their target price on shares of Abbott Laboratories from $158.00 to $159.00 and gave the stock an "overweight" rating in a research report on Thursday, April 17th. Argus upgraded shares of Abbott Laboratories to a "strong-buy" rating in a report on Tuesday, January 28th. Raymond James increased their price objective on Abbott Laboratories from $132.00 to $142.00 and gave the stock an "outperform" rating in a report on Thursday, April 17th. Finally, Wells Fargo & Company boosted their target price on Abbott Laboratories from $136.00 to $147.00 and gave the company an "overweight" rating in a research note on Thursday, April 17th. Four investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $142.59.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, EVP Andrea F. Wainer sold 949 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $131,123.33. Following the completion of the transaction, the executive vice president now directly owns 74,381 shares in the company, valued at $10,277,222.77. This represents a 1.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Eric Shroff sold 562 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total transaction of $77,651.54. Following the completion of the sale, the senior vice president now owns 31,970 shares in the company, valued at $4,417,294.90. This represents a 1.73 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 116,449 shares of company stock valued at $15,463,316. 0.46% of the stock is owned by corporate insiders.

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas' 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027. Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas' 4th Congressional District. He declared candidacy for the 2026 election. Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.